Deguelin action involves c-Met and EGFR signaling pathways in triple negative breast cancer cells.
<h4>Background</h4>Treatment of breast cancer patients with antiestrogens and aromatase inhibitor(s) or Herceptin have shown significant success in steroid receptor positive or Her-2+ breast cancers respectively. However, choice of treatments for breast cancer patients with negative stat...
Enregistré dans:
Auteurs principaux: | Rajeshwari Mehta, Harshadadevi Katta, Fatouma Alimirah, Rutulkumar Patel, Genoveva Murillo, Xinjian Peng, Miguel Muzzio, Rajendra G Mehta |
---|---|
Format: | article |
Langue: | EN |
Publié: |
Public Library of Science (PLoS)
2013
|
Sujets: | |
Accès en ligne: | https://doaj.org/article/39d2c5de925e46dda68a3b55ca44f64b |
Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|
Documents similaires
-
Co-dependency for MET and FGFR1 in basal triple-negative breast cancers
par: Vanessa Y. C. Sung, et autres
Publié: (2021) -
Recurrence biomarkers of triple negative breast cancer treated with neoadjuvant chemotherapy and anti-EGFR antibodies
par: Nina Radosevic-Robin, et autres
Publié: (2021) -
Regulation of low-density lipoprotein receptor expression in triple negative breast cancer by EGFR-MAPK signaling
par: Tiffany Scully, et autres
Publié: (2021) -
Case Report: Sequential Combination Targeted Therapy With Type I and II MET Inhibitors in a Metastatic EGFR-Mutated, MET-Amplified NSCLC Patient With Acquired MET Y1230H Mutation
par: Boning Cai, et autres
Publié: (2021) -
Coordinated regulation of WNT/β-catenin, c-Met, and integrin signalling pathways by miR-193b controls triple negative breast cancer metastatic traits
par: Chiara Giacomelli, et autres
Publié: (2021)